
Femasys (FEMY) Stock Forecast & Price Target
Femasys (FEMY) Analyst Ratings
Bulls say
Femasys Inc. is poised for growth with the anticipated commercialization of FemBloc in Europe, projected to begin in the second half of 2025 or the first half of 2026, thereby creating additional revenue streams. The company has established strategic partnerships with Spanish distributors for FemBloc, indicating strong relationships and a clear path toward market entry following the recent EU approval of the delivery system. Furthermore, promising safety and efficacy results for FemBloc suggest it may offer a superior alternative to existing permanent birth control methods, positioning Femasys favorably within the women's healthcare landscape.
Bears say
Femasys Inc. faces significant risks that contribute to a negative outlook on its stock, including potential safety signals from clinical and preclinical programs, which could impede development. The company also risks lower-than-expected efficacy in its clinical programs, with studies potentially failing to achieve statistical significance, exacerbating competitive pressures from other treatments. Furthermore, the reliance on substantial financing, estimated at ~$80 million needed through 2037 despite a cash runway extending only into mid-2025, poses a challenge to its financial viability and strategic growth.
This aggregate rating is based on analysts' research of Femasys and is not a guaranteed prediction by Public.com or investment advice.
Femasys (FEMY) Analyst Forecast & Price Prediction
Start investing in Femasys (FEMY)
Order type
Buy in
Order amount
Est. shares
0 shares